Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon May 07, 2013 9:12pm
172 Views
Post# 21354772

Somebody Goofed!!!

Somebody Goofed!!!

HEM results on Sedar tonight! Must be a total SNAFU! Who still doesn't think we need new IR leadership?

* Sales $16.6mm, down 12.7% YoY

* Revenue had a big hit in North America, similar to Trimble. Unfortunatly HEM is very levered to the US whereas Trimble is much more international. Thank goodness the non-core divison was sold! (it had a terrible quarter)

* GM 46.6%

* Net income $1.47mm

* IFRS EPS 0.07 per share

* Continuing Operations EPS 0.02 per share

* Cash on balance sheet $13.6mm

 

MD&A Comments

* Company Management continues to view the fundamentals of its global agriculture markets to be positive in the near to mid-term

* Strong OEM and Cloud results for the quarter were offset by reduced sales in our Outback and Air product lines compared to the same quarter in 2012

* North American revenues were down by 24% from the first quarter of 2012 primarily the result of a two-month delay in the launch of the Company’s new Outback STX Guidance System as poor weather conditions delayed field-test completion in early 2013. Management estimates that this delay accounted for approximately $3M in lost 1st quarter revenues, and a significant portion will not be realized in subsequent quarters during 2013

* Not sure why but they are saying net cash recieved from the Non-core sale was $13.8mm vs. $14.3mm previously mentioned. Will look for some colour as to why the difference!?

Bullboard Posts